share_log

Despite Delivering Investors Losses of 55% Over the Past 3 Years, Micro-Tech (Nanjing)Ltd (SHSE:688029) Has Been Growing Its Earnings

Despite Delivering Investors Losses of 55% Over the Past 3 Years, Micro-Tech (Nanjing)Ltd (SHSE:688029) Has Been Growing Its Earnings

尽管在过去3年中给投资者带来了55%的损失,但微科技(南京)有限公司(上海证券交易所代码:688029)的收益一直在增长
Simply Wall St ·  12/11 16:22

Micro-Tech (Nanjing) Co.,Ltd (SHSE:688029) shareholders should be happy to see the share price up 19% in the last quarter. But over the last three years we've seen a quite serious decline. Tragically, the share price declined 57% in that time. So it's good to see it climbing back up. After all, could be that the fall was overdone.

南微医学(南京)有限公司(上海证券交易所代码:688029)的股东们应该高兴地看到股价在上个季度上涨了19%。但是在过去的三年中,我们看到了一定程度的下滑。遗憾的是,股价在这段时间内下跌了57%。所以看到它再次回升是件好事。毕竟,这可能是跌幅过度。

The recent uptick of 3.2% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近上涨了3.2%可能是未来的积极信号,所以让我们来看看历史数据。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

虽然一些人仍然教授有效市场假说,但已经证明市场是过于反应的动态系统,投资者并不总是理性。一个不完美但简单的考虑市场对公司认知变化的方法是,将每股收益(EPS)的变化与股价波动进行比较。

Although the share price is down over three years, Micro-Tech (Nanjing)Ltd actually managed to grow EPS by 22% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.

虽然股价在过去三年里下跌,但南微医学(南京)有限公司实际上在此期间每年的每股收益增长了22%。考虑到股价的反应,人们可能会怀疑每股收益并不是这段时间内业务表现的良好指标(可能是由于一次性损失或收益)。或者说,公司曾经被过度炒作,因此其增长令人失望。

It's worth taking a look at other metrics, because the EPS growth doesn't seem to match with the falling share price.

值得看看其他指标,因为每股收益的增长似乎与股价下跌不匹配。

The modest 1.4% dividend yield is unlikely to be guiding the market view of the stock. We note that, in three years, revenue has actually grown at a 12% annual rate, so that doesn't seem to be a reason to sell shares. It's probably worth investigating Micro-Tech (Nanjing)Ltd further; while we may be missing something on this analysis, there might also be an opportunity.

适度的1.4%的分红派息收益率不太可能指导市场对该股票的看法。我们注意到,在三年内,营业收入实际上以每年12%的速度增长,因此这似乎不是卖出股票的理由。可能值得进一步调查南微医学(南京)有限公司;虽然我们在这项分析中可能错过了什么,但也可能存在机会。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面查看盈余和营业收入随着时间的变化(通过点击图像发现具体数值)。

big
SHSE:688029 Earnings and Revenue Growth December 12th 2024
SHSE:688029 每股收益和营业收入增长 2024年12月12日

We know that Micro-Tech (Nanjing)Ltd has improved its bottom line lately, but what does the future have in store? So we recommend checking out this free report showing consensus forecasts

我们知道南微医学(南京)有限公司最近改善了其盈利能力,但未来将会怎样呢?因此,我们建议查看这份显示共识预测的免费报告。

A Different Perspective

不同的视角

While the broader market gained around 12% in the last year, Micro-Tech (Nanjing)Ltd shareholders lost 24% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 1 warning sign we've spotted with Micro-Tech (Nanjing)Ltd .

尽管更广泛的市场在去年增长了约12%,但南微医学(南京)有限公司的股东亏损了24%(即使包括分红派息)。然而,请记住,即使是最佳股票在十二个月期间也会表现不佳。不幸的是,去年的表现可能表明存在未解决的挑战,因为其表现逊色于过去五年年化损失的6%。一般而言,长期股价疲软可能是一个不好的迹象,尽管逆势投资者可能希望研究该股票,以期实现反弹。我发现观察长期股价作为业务表现的代理非常有趣。但要真正获得洞察力,我们还需要考虑其他信息。为此,你应该注意我们发现的南微医学(南京)有限公司的一个警告信号。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果你像我一样,那么你一定不想错过这份内部人士正在购买的被低估的小型股免费名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文中引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发

    声明

    本页的译文内容由软件翻译。Moomoo将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。